CClinicalTrials.gg
RecruitingNCT05951556Updated Jul 19, 2023

Telehealth Implementation of Brain-Computer Interface

An interventional study of Use of BCI in Amyotrophic Lateral Sclerosis and Stroke, sponsored by Shirley Ryan AbilityLab. Recruiting at 1 site in United States. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Sep 2021, registered May 2022).
  • Started Sep 2021; still recruiting 5 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
16 Years to 100 Years
Sex
All
01

Study summary

Determine if Telehealth intervention can allow/empower a caregiver (who is untrained) to effectively implement and utilize a Brain-Computer Interface for communication with a participant who is "Locked in" following progression of Amyotrophic Lateral Sclerosis and other conditions.

Read the detailed description

People with Amyotrophic Lateral Sclerosis (ALS) or other conditions such as a pontine stroke may develop a condition called Locked In Syndrome (LIS) where they are unable to use alternative communication strategies such as eyegaze to allow for communication for social needs or instruction to caregivers. Brain-Computer Interface (BCI) devices have been shown in the laboratory to allow participants to effectively communicate needs and engage in social communication. However, translation of this research to the home environment has been limited. In order to be a functional option for people to utilize, BCI needs to be much easier to set up and operate.

This study is designed to determine if telehealth intervention is sufficient to allow an untrained caregiver to set up and maintain a BCI for a person with a long-term communication difficulty given LIS.

Participants will receive a computer and associated hardware to allow for set up of the BCI. Videoconference support will be provided by the research team to allow the client and caregiver to set up the device in their home. Participants will hopefully be able to use the device to generate novel communication related to their care and engage in social needs with caregivers and/or family members. Communication that is generated will be logged and times that the participant is engaged in use of the BCI when not under direct support by the researchers will also be monitored.

The hypothesis is that telehealth support will be sufficient to allow for setting up the computer. If this is true, this will make it much easier for a client to engage in use of a BCI to allow for that communication versus the current need of traveling to a clinic or other specialized setting.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Stroke

Keywords

  • locked in syndrome
03

In context

Motor Neuron Disease

717 studies on the registry are indexed under Motor Neuron Disease; 137 are open to participants now.

This study's planned enrollment of 7 is below the median of 35 across 461 interventional studies indexed under Motor Neuron Disease.

Browse Motor Neuron Disease studies →

Lead sponsor

Shirley Ryan AbilityLab is the lead sponsor of 177 studies on the registry; 43 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis leading to severe communication impairment

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    All Participants

    All Participants will receive trial device and will be trained (via Telehealth) in its use.

    Device: Use of BCI

Interventions

  • DeviceUse of BCI

    Clients will utilize BCI with training to communicate wants and needs

06

What researchers measure

Primary outcomes

  1. Log of communication

    Logs of any communication will be kept by monitoring number of accurate selections while utilizing the BCI.

    Time frame: From date of enrollment in study until the date of discontinuation of the intervention, whichever came first, assessed up to 100 months

07

Study locations

1 of 1 sites recruiting
  • ShirleyRyan AbilityLab
    Chicago, Illinois 60611, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05951556
Lead sponsor
Shirley Ryan AbilityLab
Collaborators
Albany Stratton VA Medical Center
Responsible party
Colin Franz (Attending MD, Principal investigator, Shirley Ryan AbilityLab) — Principal investigator
First posted
Jul 19, 2023
Start date
Sep 30, 2021
Primary completion
Jul 5, 2024 (estimated)
Completion
Jul 5, 2024 (estimated)
Last update
Jul 19, 2023

Study contacts

Edward C Hitchcock, OT/L
Contact
ehitchcock@sralab.org
312 238 2997
Colin Franz, MD
principal investigator · SRALAB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion